Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teniposide, Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (Transplant-Ineligible)
ChiCTR-OIC-15007636Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teniposide, cyclophosphamide and dexamethasone in multiple myeloma (MM), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Complete response rate and Overall response rate. Planned start Jan 2016; status: not yet recruiting.
02
Drugs
teniposidecyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR-OIC-15007636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-15007636.